Avalo Therapeutics Files Amendment to 8-K
Ticker: AVTX · Form: 8-K/A · Filed: Jun 24, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K/A |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financials, exhibits
Related Tickers: AVLO
TL;DR
AVLO filed an amendment to its 8-K, adding financial statements and exhibits.
AI Summary
Avalo Therapeutics, Inc. filed an amendment (No. 2) to its Form 8-K on March 27, 2024, originally filed on March 28, 2024. This amendment primarily concerns the filing of financial statements and exhibits related to the company's operations.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be important for investors to review.
Risk Assessment
Risk Level: low — This is a procedural amendment to a previous filing, not a material event disclosure.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- 001-37590 (company) — Commission File Number
- 45-0705648 (company) — IRS Employer Identification No.
- March 27, 2024 (date) — Date of earliest event reported
- March 28, 2024 (date) — Original filing date of Form 8-K
FAQ
What is the purpose of this Form 8-K/A filing?
This filing is Amendment No. 2 to the Form 8-K filed on March 28, 2024, and it pertains to the filing of financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 27, 2024.
What is the company's full name and state of incorporation?
The company's full name is Avalo Therapeutics, Inc., and it is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
What was the former name of Avalo Therapeutics, Inc.?
The former name of Avalo Therapeutics, Inc. was Cerecor Inc.
Filing Stats: 745 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-24 16:01:28
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20240327.htm (8-K/A) — 31KB
- ex-231eyconsentrestated.htm (EX-23.1) — 2KB
- ex-991almatarestatedaudite.htm (EX-99.1) — 181KB
- ex-992almatarestatedprofor.htm (EX-99.2) — 131KB
- 0001628280-24-029561.txt ( ) — 499KB
- avtx-20240327.xsd (EX-101.SCH) — 2KB
- avtx-20240327_lab.xml (EX-101.LAB) — 21KB
- avtx-20240327_pre.xml (EX-101.PRE) — 12KB
- avtx-20240327_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired. The audited financial statements of Almata as of December 31, 2023 and for the period from April 28, 2023 (date of inception) to December 31, 2023 and the related notes are attached hereto as Exhibit 99.1 and incorporated herein by reference. (b) Pro Forma Financial Information. Unaudited pro forma condensed combined financial information, which includes pro forma condensed combined statements of operations for the year ended December 31, 2023 and the three months ended March 31, 2024 and the notes related thereto, are filed as Exhibit 99.2 to this report and incorporated herein by reference. (d) Exhibits: Exhibit No. Description 23.1 Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm. 99.1 Audited financial statements of Almata as of December 31, 2023 and for the period from April 28, 2023 (date of inception) to December 31, 2023. 99.2 Unaudited pro forma combined financial information of Almata and Avalo for the three months ended March 31, 2024 and for the year ended December 31, 2023. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: June 24, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2